FATE) has partnered with the University of California San Diego to develop off-the-shelf, chimeric antigen receptor
(CAR)-targeted natural killer (NK) cell cancer immunotherapies.
Riviere, "The promise and potential pitfalls of chimeric antigen receptors
," Current Opinion in Immunology, vol.
Biopharmaceutical company Juno Therapeutics develops cell-based cancer immunotherapies based on its chimeric antigen receptor
and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
Design of chimeric antigen receptors
with integrated controllable transient functions
Using a process called adoptive cell transfer (ACT), T cells have been engineered to produce chimeric antigen receptors
(CARs), a surface receptor that allows T cells to recognize tumor-specific proteins and then kill the targeted tumor cells.
Nasdaq: PRCT) announced today that its five-year agreement with Bristol-Myers Squibb to collaborate on the development of T cell antigen receptors
for autoimmune diseases will end, as scheduled, in February 1995.
Cellectis, a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors
to target and eradicate cancer in France.
The granted claims are not limited to specific Chimeric Antigen Receptors
or specific methods of generating allogeneic CAR T- cells, such as genome editing or genetic engineering.
It often takes the form of a bull s eye with a central cluster of antigen receptors
surrounded by a ring of adhesion molecules.
According to TxCell, Dr Danos is another significant addition to its SAB, which already includes leading experts in immunology, T-cell biology and chimeric antigen receptors
The deal will see the partners giving $100 million to MD Anderson for a CAR-T technology, made through a process in which researchers remove T cells from a patient's blood and provide them with targeting mechanisms called chimeric antigen receptors
(CARs), which seek out and bind to proteins that cancer cells express.
The firms plan to engineer immune cells with fully human chimeric antigen receptors
and T-cell receptors directed to disease-specific cell surface antigens in order to allow the precise engagement and killing of tumour cells.
In both models, administration of the peptides resulted in reduced titres of anti-AChR antibodies and lower numbers of anti-AChR T-cells, based on the induction of antibodies that bound to the corresponding B and T cell antigen receptors